Background: Uncertainty exists about the link between omega-3 fatty acid, omega-6 fatty
acid, and total polyunsaturated fatty acid (PUFA) intake and mortality in atherosclerotic …

The objective of this study was to characterize clinician response following standardization
of pharmacogenetic (PGx) clinical decision support alerts at University of Florida (UF) …

Based on a wealth of evidence, aspirin is one of the cornerstones of secondary prevention of
cardiovascular disease. However, despite several studies showing efficacy also in primary …

Dual antiplatelet therapy (DAPT) is the standard approach to prevent thrombotic events in
patients undergoing percutaneous coronary intervention and presenting with chronic or …

Introduction In patients with acute coronary syndrome (ACS), the ischemic benefit of
antithrombotic treatment is counterbalanced by the risk of bleeding. The recognition that …

Abstract Background Genetic-guided P2Y12 inhibitor selection has been proposed to
reduce ischemic events by identifying CYP2C19 loss-of-function (LOF) carriers at increased …

Loss‐of‐function (LoF) alleles of cytochrome P450 2C19 (CYP2C19), which are prevalent in
East Asians, are linked to high platelet reactivity (HPR) phenotype and poor prognosis. We …

Background Ticagrelor improves clinical outcomes in patients with acute coronary
syndromes compared with clopidogrel. Ticagrelor also inhibits cell uptake of adenosine and …

Background Although there is a growing body of evidence that CYP2C19 genotyping can be
beneficial when considering treatment with clopidogrel after percutaneous coronary …

Background P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy
(DAPT) may balance ischemic and bleeding risks in patients with acute coronary syndrome …